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Abstract
Paraquat (PQ) is a neurotoxic herbicide that induces superoxide formation. Although it is known that its toxic properties are
linked to ROS production, the cellular response to PQ is still poorly understood. We reported previously that treatment with
PQ induced genome-wide changes in pre-mRNA splicing. Here, we investigated the molecular mechanism underlying PQ-
induced pre-mRNA splicing alterations. We show that PQ treatment leads to the phosphorylation and nuclear accumulation
of SRPK2, a member of the family of serine/arginine (SR) protein-specific kinases. Concomitantly, we observed increased
phosphorylation of SR proteins. Site-specific mutagenesis identified a single serine residue that is necessary and sufficient
for nuclear localization of SRPK2. Transfection of a phosphomimetic mutant modified splice site selection of the E1A
minigene splicing reporter similar to PQ-treatment. Finally, we found that PQ induces DNA damage and vice versa that
genotoxic treatments are also able to promote SRPK2 phosphorylation and nuclear localization. Consistent with these
observations, treatment with PQ, cisplatin or c-radiation promote changes in the splicing pattern of genes involved in DNA
repair, cell cycle control, and apoptosis. Altogether, our findings reveal a novel regulatory mechanism that connects PQ to
the DNA damage response and to the modulation of alternative splicing via SRPK2 phosphorylation.
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Introduction
Parkinson’s Disease (PD) is the second most common progres-
sive neurodegenerative disorder of the central nervous system.
Epidemiological studies suggest that PD is a multifactorial disorder
probably arising from polygenic inheritance and gene–environ-
mental interactions. Exposure to pesticides and to the herbicide
paraquat (PQ, 1,19-dimethyl-4,49-bipyridinium) is known to
increase the risk of developing PD. PQ uncouples the mitochon-
drial electron transport chain, which induces superoxide formation
[1]. Thus its toxic properties support the hypothesis that neuronal
damage in PD may arise from a mechanism of oxidative stress.
Since in recent years PQ has become an increasingly popular
model for studying the etiology of PD (15, 16), it is important to
understand the molecular mechanism underlying PQ-induced
toxicity to neural cells.
Recently, we reported that treatment of the human neuroblas-
toma cells SH-SY5Y with PQ induces extensive changes in
alternative pre-mRNA splicing (AS) [2]. Pre-mRNA splicing is a
crucial step of eukaryotic gene expression that has emerged in
recent years as a major regulatory mechanism of cell cycle and
apoptosis [3,4]. Changes in AS have been observed in PD and in
other neurodegenerative disorders [5]. Indeed, in response to
cellular stress AS can be controlled by specific signal transduction
pathways that lead to post-translational modifications of splicing
factors and to changes in their activity and/or subcellular
localization [6].
SR protein kinases (SRPKs) are a family of protein kinases that
phosphorylate serine-arginine-rich proteins (SR proteins), which
are important regulators of alternative splicing [7]. While SRPK1
is predominantly expressed in pancreas, SRPK2 is highly
expressed in brain, and both are co-expressed in other human
tissues and in many experimentally used cell lines [8]. SRPK1 and
2 are predominately localized in the cytoplasm, where they
phosphorylate SR proteins that can thus be re-imported into the
nucleus [9]. SRPK1 and 2 are highly similar proteins that contain
a bipartite kinase domain separated by a unique spacer region. It
has been shown that removal of the spacer in SRPK1 has little
effect on the kinase activity, but triggers the translocation of the
protein to the nucleus and consequently induces aggregation of
hyperphosphorylated SR proteins in nuclear speckles [10].
Nuclear translocation of SRPK1 was recently reported to occur
also upon Akt activation by EGF treatment [11].
Here we show that PQ treatment of SH-SY5Y human
neuroblastoma cells leads to the re-localization of SRPK2 to the
cell nucleus, to SR protein phosphorylation and to their
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accumulation in nuclear speckles. We find that phosphorylation of
a specific serine residue is necessary and sufficient to localize
SRPK2 to the nucleus and to modify the alternative splicing
pattern of a minigene splicing reporter. In addition, we show that
PQ treatment induces formation of H2AX foci that are indicative
of DNA double-strand breaks. Consistent with this, we observe
that also cisplatin and gamma irradiation induce nuclear
accumulation of SRPK2. Collectively, these data indicate that
PQ-induced AS changes are mediated by modificaton and
relocalization of SRPK2 that phosphorylate splicing factors.
Results
Treatment with PQ induces modifications in the
intracellular distribution and in the phosphorylation
status of splicing factors
In a recent report we described the result of a splicing-sensitive
microarray analysis of human neuroblastoma SH-SY5Y cells
treated with paraquat (PQ) [2]. This analysis, despite detecting
extensive changes in alternative splicing, did not show differential
expression of any gene encoding splicing regulatory factors. This
finding prompted us to test whether PQ induced posttranslational
modifications and/or changes in the intracellular distribution of
specific splicing regulators. We examined by immunofluorescence
microscopy the intracellular distribution of several splicing
regulatory proteins in cells incubated with 0.75 mM PQ for
18 hours. Using a monoclonal antibody that specifically recognizes
phosphorylated SC35, we detected enlarged nuclear speckles
(Figure 1A, upper row, and Figure S1). Relocalization of SR
proteins to nuclear speckles in PQ-treated cells was further
confirmed by the analysis of the distribution of GFP-ASF/SF2 in
treated cells (Figure 1A, middle row). In contrast, PQ did not affect
the intracellular distribution of members of the hnRNP family of
splicing regulators (such as hnRNP A1, Figure 1A, bottom row,
and hnRNP H and hnRNPK, data not shown), which has been
reported to relocate to the cytoplasm following diverse types of
stress treatments [12,13]. We also checked expression of different
hnRNP proteins by western blotting without detecting any
significant variation (Figure S2).
Formation of enlarged nuclear speckles has been previously
linked to hyperphosphorylation of SR proteins [14,15]. We thus
tested the phosphorylation status of SR proteins by western
blotting using mAb104, a monoclonal antibody that specifically
recognizes the common phosphoepitopes of classical SR proteins
[16]. In response to PQ treatment, we observed an increase in the
signal for all the classical SR proteins recognized by the antibody
(Figure 1B). To check for possible alterations of protein levels upon
PQ treatment, SR proteins were also visualized with the 16H3
antibody, which recognizes RS domains of different SR proteins
regardless of their phosphorylation status, and with anti–ASF/SF2
and anti-SRp20 antibodies (Figure 1C). Since the protein levels of
the SR proteins remained unchanged, our results collectively
demonstrate that PQ treatment increases the phosphorylation of
SR proteins.
To date, several kinases have been reported to phosphorylate
SR proteins. These include DNA topoisomerase I [17], SRPK1–3
[8,18–20] and the family of CLK1/Sty kinases [21]. Upon PQ
treatment we did not detect any appreciable change in either the
expression or the intracellular distribution of CLK1/Sty (data not
shown). In contrast, PQ induced the accumulation of SRPK2 in
the cell nucleus (Figure 2A). Quantification of fluorescence images
from individual cells revealed that the nuclear to cytoplasmic (N/
C) ratio of the SRPK2 signal was,0.4 in untreated cells and,2.3
in cells treated with PQ (Figure 2B). To test if the observed
increase in SR protein phosphorylation was due to SRPK activity,
we knocked down both SRPK1 and SRPK2 using specific
shRNAs (Figure 2C). Silencing was more efficient for SRPK2
than for SRPK1. We then used the phospho-specific antibody
mAb104 to test the effect of PQ on the phosphorylation of SR
proteins in SRPK depleted cells. As shown in Figure 2D, PQ
treatment no longer resulted in increased phosphorylation of
SRp55, SRp40, SRp30 and SRP20 in cells depleted of the two
kinases. Interestingly, PQ was still able to promote phosphoryla-
tion of SRp75, suggesting that SRPKs are not redundant and have
some substrate specificity. To control for equal loading of the
samples, SR proteins were also visualized with the 16H3 antibody,
which recognizes SR proteins regardless of their phosphorylation
status (Figure 2E).
SRPK2 phosphorylation at the Ser-581 residue is required
for its translocation to the nucleus after paraquat
treatment
SRPK2 normally appears on SDS-PAGE as two closely
migrating bands. In extracts prepared from PQ-treated cells we
observed an increased intensity of the slower migrating SRPK2
species at the expense of the faster migrating species (Figure 3A).
To determine whether the mobility shift of SRPK2 was due to
increased phosphorylation, the extracts were treated with calf
intestinal phosphatase (CIP). After incubation with the phospha-
tase, the slower migrating SRPK2 band in both the untreated and
the PQ-treated cells collapsed to a single faster-migrating form,
confirming that the mobility shift was due to increased phosphor-
ylation (Figure 3B).
To identify the protein domain required for the nuclear
localization of SRPK2, we created a set of deletion and point
mutations in SRPK2. In particular to determine whether there
was a link between translocation to the nucleus and phosphory-
lation of SRPK2, we generated point mutations in serine and
tyrosine residues that were predicted phosphorylation targets
according to the software Scansite [22]. The scheme of all the
designed mutants is presented in Figure S3A. All the mutant
proteins were examined for their intracellular localization both in
untreated and in PQ-treated cells (Figure S3B). Interestingly and
in contrast to SRPK1 [23], deletion of the spacer domain did not
affect SRPK2 subcellular localization both in SH-SY5Y and in
HeLa cells (Figure S3B and data not shown, respectively). As
shown in Figure 3C, one mutant, SRPK2(S581A) was unable to
relocalize to the nucleus upon PQ treatment. Quantification of the
nucleus to cytoplasm (N/C) ratio for SRPK2(S581A) in PQ-
treated cells indicated an approximately 3-fold reduced N/C ratio
compared to wild type SRPK2 (Figure 3D). In contrast, the
respective phosphomimetic mutation, S581D, was nuclear even in
the absence of PQ. Serine 581 is located in the highly conserved
C-terminal kinase domain within a putative casein kinase 2
consensus sequence (S/T-X-X-E/D, Figure 3E). Taken together,
these results indicate that phopshorylation of serine 581 is required
for nuclear accumulation of SRPK2.
Nuclear SRPK2 modifies splice site selection
Since PQ treatment leads to the translocation of SRPK2 from
the cytoplasm to the nucleus, and to hyperphosphorylation and
accumulation of SR proteins in nuclear speckles, we reasoned that
these events may affect splice site selection by modifying the
balance between SR proteins and other splicing regulatory
proteins, e.g. hnRNP proteins. To test this hypothesis we used
the Adenovirus 2 E1A minigene whose pre-mRNA can be
processed into five well-characterized mRNAs (Figure 4A). Three
Paraquat-Induced SRPK2 Relocalization
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major forms, 13 S, 12 S and 9 S derive from the selection of
alternative 59 splice sites [24]. Two minor forms, 11 S and 10 S,
involve the minor usage of a cryptic upstream 39 splice site
localized in an intron [25]. The splice site selection on this pre-
mRNA depends on the relative concentrations of hnRNP A1 and
SR proteins [12]. As illustrated in Figure 4B (lane 1), transfection
of the E1A minigene in SH-SY5Y cells generated variable
amounts of the five reported RNA species, reflecting the
differential usage of the alternative 59 and 39 splice sites. PQ
treatment resulted in a shift in splicing favoring use of the most
distal 59 splice site that gives raise to the 9 S RNA isoform
(Figure 4B, lane 2, and 4C).
Next we asked whether the modification of the alternative
splicing pattern of the E1A minigene observed in PQ-treated cells
was a consequence of the increased level of SRPK2 in the nucleus.
To this end, cells were co-transfected with the E1A minigene and
with constructs expressing HA-tagged wild type HA–SRPK2 or
the mutant HA–SRPK2(S581D) (Figure 4D). The splicing pattern
Figure 1. Increased phosphorylation of SR proteins in PQ-treated cells. A. PQ induced relocalization of SR proteins in the nucleus of treated
cells. SH-SY5Y cells treated with vehicle or with 0.75 mM PQ for 18 h were immunostained with an anti-SC35 antibody (upper row), transiently
transfected with GFP-ASF/SF2 (middle row), or with GFP-hnRNPA1 (lower row). Nuclei were stained with DAPI. B. Increased phosphorylation of SR
proteins in PQ-treated cells. Total extract of control or PQ-treated cells was probed with mAb104 to determine the phosphorylation state of classical
SR proteins. C. The same extracts used for the Western blot shown in panel B were probed with the 16H3 monoclonal antibody that detects SR
proteins regardless of their phosphorylation status, with anti ASF/SF2 and anti-SRp20 monoclonal antibodies. Actin was used as loading control.
doi:10.1371/journal.pone.0061980.g001
Paraquat-Induced SRPK2 Relocalization
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of E1A was then compared between untreated cells and cells
treated with PQ. As shown in Figure 4E and 4F, expression of the
phospho-mimetic mutant SRPK2(S581D) in untreated cells
increased production of the 9 S splice variant. Interestingly, when
expressing the nucleus-enriched SRPK2(S581D) mutant, treat-
ment with PQ did not further increase the production of the 9 S
isoform indicating that the nuclear localization of SRPK2 is
Figure 2. Nuclear translocation of SRPK2 and phosphorylation of SR proteins in response to PQ. A. Representative confocal micrographs
of SH-SY5Y cells stained with an SRPK2-specific antibody. Upper row: cells treated with vehicle; lower row: cells treated with 0.75 mM PQ for 18 h.
DAPI was used to identify the nuclei. B. The average nuclear to cytoplasmic ratio (N/C) ratio of SRPK2 fluorescent signal was determined for 50 cells as
described in Materials and Methods. *** indicates p,0.001 treated vs. control group by unpaired t-test. C. RNA-mediated silencing strongly reduced
SRPK1 and SRPK2 expression. Western blot analysis of the expression level of SRPK proteins in the same extract used for the Western blot shown in
figure 2D and 2E. CPSF73K was used as loading control. D. Silencing of SRPK1 and SRPK2 abolishes PQ-mediated phosphorylation of SR proteins.
Western blot analysis of nuclear extracts prepared from control SH-SY5Y cells treated with vehicle or with PQ, and from cells depleted of both SRPK1
and SRPK2. Phosphorylated SR proteins were detected with mab104. E. To control for equal loading of the samples SR proteins were also detected
with mab16H3.
doi:10.1371/journal.pone.0061980.g002
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Figure 3. Phosphorylation of Ser581 is required for the nuclear localization of SRPK2. A. Western blots of total cell extract prepared from
untreated SH-SY5Y cells or from cells treated with PQ for the indicated times. The blot was probed with an anti-SRPK2 antibody. Upon PQ treatment
an increase of the slower migrating band (indicated by an arrowhead) could be observed. B. SRPK2 phosphorylation was confirmed by CIP treatment.
Total cell lysates prepared from untreated cells and from cells treated with PQ were incubated with calf intestinal phosphatase (CIP) as described in
Paraquat-Induced SRPK2 Relocalization
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sufficient to induce changes in the splicing pattern of the E1A
transcript.
DNA damage induces nuclear translocation of SRPK2 and
changes in splice-site selection
PQ is an uncoupler of the mitochondrial electron transport
chain that induces superoxide formation [1] and oxidative stress
[26]. Consequences of oxidative stress are DNA lesions, including
oxidized DNA bases, abasic sites, and single-strand and double-
strand breaks (SSBs and DSBs). Therefore, we wondered whether
the translocation of SRPK2 to the nucleus might be a consequence
of the cellular response to DNA damage. Indeed, the activation of
the DNA damage response (DDR) is suggested by the observation
that several genes related to this pathway are differentially
expressed in PQ-treated cells (Table 1). To monitor PQ-induced
DNA damage, we checked the phosphorylation status of the Ser-
139 residue of the histone variant H2AX, forming a˜H2AX (for
review see [27]) in cells treated with PQ for different lengths of
times (Figure 5A). The time of appearance of a˜H2AX foci in PQ-
treated cells paralleled the relocalization of SRPK2 from the
cytoplasm to the nucleus, suggesting that the two events may be
connected. To further strengthen the link between intracellular
distribution of SRPK2 and the response to DNA damage, we
tested the effect of chemical inhibitors of some of the signaling
kinases involved in this pathway. Recent studies in yeast and
metazoa have revealed that cyclin-dependent kinases (CDKs) play
an active role in the response to DNA damage [28,29]. We thus
treated SH-SY5Y cells with the general CDK inhibitor roscov-
itine. Consistent with earlier reports [30,31], incubation with
roscovitine strongly reduced the appearance of cH2AX foci after
PQ treatment (Figure 5B). Interestingly, in the presence of
roscovitine, PQ treatment no longer promoted the accumulation
of SRPK2 in the nucleus (Figure 5C). A similar effect was obtained
in the presence of caffeine, a potent inhibitor of ATM and ATR,
crucial signaling kinases that mediate the response to DNA
damage (Figure 5C). Next, we verified whether other genotoxic
treatments also promoted nuclear translocation of SRPK2. As
shown in Figure 5D, treatment with 20 mM cisplatin for 18 hours
or irradiation with 10 Gy induced both accumulation of endog-
enous SRPK2 in the nucleus and its hyperphosphorylation
(Figure 5E). Similar results were obtained in HEK 293 cells (data
not shown). Taken together these results show that activation of
the DDR results in an increase of the nuclear pool of SRPK2.
The DDR includes gene expression programs that control cell
cycle, DNA repair and apoptosis. Alternative splicing is known to
regulate many key genes in these pathways [3,32]. Consistent with
this notion, several putative alternative splicing events that were
identified in our splicing-sensitive microarray analysis of PQ-
treated cells occurred in genes involved in DNA repair, cell cycle,
and cell death [16]. To experimentally validate a subset of these
splicing events affecting internal exons, we peformend RT-PCR
analysis. As illustrated in Figure 6A, PQ treatment induced
changes in the AS pattern of genes involved in apoptosis (APAF1,
BIN1), cell cycle control (H-RAS; SKP2), and DNA repair
(ERRC1). Interestingly, in the case of APAF1 and HRAS the ASE
responded not only to PQ but also to c-radiation or cisplatin
(Figure 6B and 6C, respectively). Moreover similarly to PQ,
cisplatin treatment of SH-SY5Y transiently transfected with the
E1A splicing reporter construct stimulated the use of the most
distal 59 splice site, which gives rise to the 9 S isoform. In
conclusion, these experiments strongly suggest that DNA damage
can trigger changes in the splicing pattern of cellular genes by
modifying the ratio between cytoplasmic and nuclear SRPK2.
Discussion
In this report we investigated the molecular mechanism
underlying the changes in alternative splicing that are induced
by PQ treatment of SH-SY5Y neuroblastoma cells. We show that
PQ leads to the phosphorylation and the accumulation of SRPK2
in the cell nucleus, and to increased phosphorylation of SR
proteins. Relocalization of SRPK2 correlates with changes in the
alternative splicing pattern of the E1A splicing reporter and of
endogenous transcripts.
The molecular mechanisms that allow various stress stimuli to
be transmitted to the nucleus are still only partially understood.
Most research has concentrated on the elucidation of signal
transduction pathways that target transcription factors. A few
reports have however indicated that alternative pre-mRNA
splicing is also a target of stress signaling. Osmotic stress was
shown to induce the relocalization of hnRNPA/B the cytoplasm,
resulting in changes in the alternative splicing pattern of an
adenovirus E1A pre-mRNA splicing reporter [12]. Osmotic stress
also promotes nuclear accumulation of SRPK1, the ubiquitously
expressed paralogue of SRPK2 [15].
We demonstrate here that a phosphomimetic substitution of a
serine residue located in the C-terminal kinase domain is necessary
and sufficient to promote the accumulation of SRPK2 in the
nucleus in the absence of PQ. In contrast, substitution of this
serine with a non-phosphorylatable alanine residue prevents PQ-
induced translocation. Interestingly, we found that caffeine and
roscovitine prevent nuclear accumulation of SRPK2 upon PQ
treatment. Moreover, we observed the formation of cH2AX foci
in PQ-treated cells. The kinetics of foci appearance closely
correlated with the nuclear accumulation of SRPK2, suggesting
that SRPK2 relocalization may be due to the activation of the
DDR. Consistent with this idea, we found that cisplatin treatment
and c irradiation also induced an increase in nuclear SRPK2.
The biological function of SR proteins is regulated by cycles of
reversible phosphorylation [33]. Not surprisingly, phosphorylation
of SR protein is under the tight control of specific protein kinases
and phosphatases [34]. Increased amounts of SRPK2 in the
nucleus may alter the balance between SR protein kinases and
phosphatases leading to the hyperphosphorylation of SR proteins,
which in turn modulates splice site selection (Figure 7). Consistent
with this idea, we observed increased phosphorylation of most SR
proteins and a shift in splice site selection of the E1A minigene
reporter towards the 9 S mRNA variant. Similar effects on
SRPK1 localization and E1A splicing are induced by osmotic
stress [15]. Therefore, the redistribution of SRPKs may represent
a more general mechanism by which cells transduce stress signals
to change alternative splicing of key genes in cell fate determina-
tion.
Material and methods. C. Representative confocal micrographs of SH-SY5Y cells transfected with a construct expressing HA-tagged SRPK2, HA-
SRPK2(S581A), or HA-SRPK2(S581D). Upper row: DAPI; middle row: cells stained with an HA-specific antibody; lower row: merge of the DAPI and
antibody signals. D. The nuclear to cytoplasmic ratio (N/C) of the fluorescence signal was determined for 50 transfected cells. The graph shows the
average N/C ratio of SRPK2 signal measured as described in Materials and Methods. E. *** indicates p,0.0001 of groups compared by one-way
ANOVA and Tukey post-test analysis. F. Sequence alignment of the 577–586 aa region in SRPK2 highlighting conservation of CK2 consensus sites
across species. A black, vertical bar indicates the conserved serine.
doi:10.1371/journal.pone.0061980.g003
Paraquat-Induced SRPK2 Relocalization
PLOS ONE | www.plosone.org 6 April 2013 | Volume 8 | Issue 4 | e61980
Figure 4. PQ treatment or nuclear SRPK2 affect splice site selection of the E1Aminigene transcript. A. Schematic diagram illustrating the
structure of the construct and the splicing pattern of the E1A minigene reporter. Arrows mark the position of the primers used for PCR analysis. The
alternative 59 splice site and splicing events that generate the different mRNA variants are indicated. B. Representative agarose gel of the splicing
assay. SH-SY5Y cells were transiently transfected with the E1A reporter plasmid. 24 h after transfection cells were treated PQ. Total RNA was then
isolated and the alternative splicing pattern of the E1A transcripts was determined by RT-PCR. The treatment with PQ induced an increase of the
production of the 9 S transcript variant with respect to the other isoforms. C. Densitometric analysis of the E1A splicing products (mean 6 S.E., n = 3)
in cells treated with vehicle or with PQ. *** indicates p,0.001, and * indicates D. p,0.05, compared with control by paired, two-tailed Student’s t test.
E. Western blot analysis of the expression level of HA-tagged wild type and the S581D mutant in untreated and in PQ-treated SH-SY5Y cells. Blots
were probed with an anti-HA antibody. Actin was used as loading control. F. SH-SY5Y cells were transiently transfected with the E1A splicing reporter
minigene alone or together with expression plasmids coding for HA-tagged wild type SRPK2 or with the S581D mutant. RNA and protein fractions
were simultaneously prepared. The alternative splicing pattern of the E1A transcripts was determined by RT-PCR. G. Densitometric analysis of the
splicing products (mean 6 S.E., n = 3) in untreated and PQ-treated cells. The relative levels of 13 S, 12 S, and 9 S mRNAs were quantitated as
described in Materials and Methods. *** indicates p,0.001, * * indicates p,0.01, by one-way ANOVA and Dunnett’s post test.
doi:10.1371/journal.pone.0061980.g004
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Figure 5. Genotoxic stress induces nuclear accumulation and phosphorylation of SRPK2. A. PQ induces DNA damage. Representative
confocal micrographs of SH-SY5Y cells treated with PQ and fixed at the indicated time-points. Cells were stained with an anti-cH2AX antibody (upper
row) or with an antibody specific for SRPK2 (lower row). B. Inhibition of PQ-induced H2AX phosphorylation by roscovitine. Representative confocal
micrographs of SH-SY5Y cells incubated with 10 mM roscovitine and PQ treatment. a˜H2AX was detected by immunocytochemistry; nuclei were
stained with DAPI. C. Inhibition of the DDR blocks nuclear localization of SRPK2. Representative confocal micrographs of control SH-SY5Y cells (first
row), or SH-SY5Y cells incubated with PQ alone (second row), or with PQ and with 10 mM roscovitine (third row), or with PQ and 10 mM caffeine (forth
row). SRPK2 was detected by immunocytochemistry; nuclei were stained with DAPI. D. Genotoxic treatments induce nuclear localization of SRPK2.
Representative confocal micrographs of untreated SH-SY5Y cells (upper row) or cells treated with 20 mM cisplatin for 18 h (middle row) or irradiated
with 10 Gy (lower row) were stained with DAPI and with an anti-SRPK2 antibody. E. Genotoxic treatments induce hyperphosphorylation of SRPK2.
Western blots of total cell extract prepared from untreated SH-SY5Y cells or from cells treated with PQ, or with cisplatin for the indicated times. The
blot was probed with an anti-SRPK2 antibody. Actin was used as loading control. The slower migrating band is indicated by an arrow.
doi:10.1371/journal.pone.0061980.g005
Paraquat-Induced SRPK2 Relocalization
PLOS ONE | www.plosone.org 8 April 2013 | Volume 8 | Issue 4 | e61980
Materials and Methods
Constructs
pME-HAmSRPK2 [45] was used as a template to derive all the
SRPK2 mutants. The spacer-deleted mutant was obtained by
double digestion of pME-HAmSRPK2 with BamHI and HindIII
followed by fill-in and ligation of the vector. The N-terminus
deleted was obtained by a first amplification with the oligonucle-
otides Nterm-FW (59- GTCGACGCGGCCGCGGA-
GATTCTGGGGTCAGATG -39) and HindIII-REV (59-
CGGAAGCTTCTGCAGAGGT -39)), and then subcloning in
pME-HAmSRPK2 digested with HindIII/SalI. All other mutants
were obtained thorough site directed mutagenesis (for the
complete list of oligonucleotide sequences used in the mutagenesis
see supplementary table S2). The plasmid p-hSRPK2-FLAG was
obtained by inserting a FLAG tag in pCMV6-XL5-hSRPK2
(SC107542, OriGene). PCR was performed using the oligonucle-
otides hSRPK2-fw (59-TATGTCAGTTAACTCTGAGAAG-
TCGT-39) and hSRPK2-rev (59-ACTACTTATCGTCGT-
CATCCTTGTAATCAATGTTAACAGAATTCAACCAAG-
GAT-39), and the Phusion Hot Start High-Fidelity DNA
Polymerase (F-540 S, Finnzymes). The PCR product was cleaved
with NotI and inserted in pCDNA3. All the constructs were
verified by nucleotide sequencing.
To generate silencing constructs for SRPK1 and SRPK2,
sequences coding for short hairpin RNAs (shRNAs) were inserted
as double-stranded oligonucleotides into pSUPuro between the
BglII and HindIII sites as described [35,36]. In each construct, the
sense and antisense sequences of the target sequence (SRPK1: 59-
GGACAAAGCCCAAAGGAAA-39; SRPK2: 59- GCGA-
GAAGCTGAAAGGAAA-39) are separated by a 9 nt spacer
(TTCAAGAGA) that allows the formation of a hairpin loop.
These vectors are referred to as pSUPuro-SRPK1 and pSUPuro-
SRPK2. To generate the pLV-TH SRPK1 and SRPK2 plasmids,
the pSUPuro plasmids were digested with BstXI and SalI and the
H1-shRNA cassette was inserted into the same sites of pLV-TH
[37].
Cell culture and drug treatments
Human neuroblastoma SH-SY5Y were cultured in D-MEM/F-
12 medium with GlutaMAXTM (Gibco, Invitrogen, UK), 10%
FBS, 100 Units/mL penicillin G, 100 mg/ml streptomycin/
penicillin (Euroclone, Milano, Italy). After having reached
confluence, cells were reseeded at 36106cells in 100 mm dish.
Paraquat (N,N9-dimethyl-4,49-bipyridinium dichloride, Sigma-
Aldrich) treatment was carried out essentially as described in
(Maracchioni, et al., 2007) but for 18 h at 0.75 mM concentration.
Treatment with cisplatin (Sigma-Aldrich) was performed for 18 h
at 20 mM concentration. Roscovitine was used at a concentration
of 10 mM and caffeine at 10 mM.
Transfections for RNA extraction or immunoblotting were
performed with polyethylenimine (PEI, 40,872-7, Sigma, 100 mM
in H20 pH 7.00) according to the manufacturer’s instruction. The
transfected cells were incubated for further 24 or 48 h before lysis.
For immunofluorescence analysis, cells were seeded in a 6-well
plate containing a coverslip in each well. The next day 3 mg
plasmid DNA was transfected using Transfast (Promega).
RNA interference
LV-ttR Krab-dsRed-transduced SH-SY5Y cells were incubated
with recombinant lentiviruses containing the shRNA expression
cassettes for SRPK1 and SRPK2 [37]. To allow fluorescence-
activated cell sorting of dsRed/GFP double positive cells,
doxycyclin was added to the growth medium 48 h before sorting.
Cell sorting positive cells was performed on a FACS ARIA
apparatus (Becton Dickinson, Franklin Lakes, NJ, USA). To
generate the inducible SRPK1/2 double knockdown cell line, the
sorted SH-SY5Y SRPK2 shRNA cell line was retransduced with
LV-TH SRPK1 shRNA viral supernatant. To induce silencing of
SRPKs cells were incubated for five days with 5 mg/ml doxycyclin.
Immunofluorescence and confocal microscopy analysis
Cells grown on the glass coverslips were fixed with 4%
paraformaldehyde in PBS for 10 min and permeabilized with
CKS solution (Hepes 20 mM, sucrose 300 mM, NaCl 50 mM,
MgCl2 3 mM, Triton 0,2%) cold for 5 min. After blocking with
FBS 10% in PBS with 0,05% Tween for 30 min, coverslips were
incubated for 1 h in a humid chamber with the following primary
antibodies in PBS containing 0,2% BSA: goat polyclonal anti-
SRPK2 (P-19, sc-11308, Santa Cruz Biotechnologies), mouse
monoclonal anti-SRPK2 (611118, BD Biosciences), mouse mono-
clonal anti-HA (Clone 6E2, 2367, Cell Signaling Technology),
rabbit polyclonal anti-HA (Y-11, sc-805, Santa Cruz Biotechnol-
Table 1. Differentially expressed genes involved in DNA damage response.
Accession Number Gene Symbol Description
Log2Fold
expression P.Value
NM_032043 BRIP1 BRCA1 interacting protein C-terminal helicase 1 21.00 3,5361023
NM_005194 CEBPB CCAAT/enhancer binding protein (C/EBP), beta 1.80 4,4761028
NM_001806 CEBPG CCAAT/enhancer binding protein (C/EBP), gamma 1.03 5,8561029
NM_022111 CLSPN claspin homolog (Xenopus laevis) 21.14 1,5561023
NM_000107 DDB2 damage-specific DNA binding protein 2, 48 kDa 1.24 2,0961029
NM_004083 DDIT3 DNA-damage-inducible transcript 3 3.46 8,4761028
NM_019058 DDIT4 DNA-damage-inducible transcript 4 2.51 3,4661027
NM_001031716 OBFC2A oligonucleotide/oligosaccharide-binding fold containing 2A 1.19 1,1461024
NM_006502 POLH polymerase (DNA directed), eta 1.45 1,0261029
NM_018137 PRMT6 protein arginine methyltransferase 6 21.14 5,5961029
NM_004219 PTTG1 pituitary tumor-transforming 1 21.03 1,196103
NM_031271 TEX15 testis expressed 15 21.59 1,156103
doi:10.1371/journal.pone.0061980.t001
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ogies), or mouse monoclonal anti-SC35 (S4045, Ascites Fluid,
Sigma). After washing three times with PBS plus 0.2% BSA, the
coverslips were stained with the respective fluor-conjugated
secondary antibody in PBS and 0.2% BSA. The secondary
antibodies were: Alexa 488-conjugated donkey anti-goat (A11055,
Molecular Probes), Alexa 488-conjugated goat anti-mouse
(A11001, Molecular Probes), Alexa 488-conjugated goat anti-
rabbit IgG (A-11070, Molecular Probes), and Alexa 546-conju-
gated donkey anti-mouse (A10036, Molecular Probes). After dark
incubation for 1 h, coverslips were washed three times with PBS
plus 0.2% BSA, incubated in a solution containing 4,6-diamidino-
2-phenylindole (DAPI, D9542, Sigma) 1 mg/mL in PBS for
10 min at RT, and mounted with FluorSave Reagent (345789,
20 mL, Calbiochem). The fluorescence 8-bit images were
collected with a Leica TCS SP2 AOBS confocal microscope with
the 636 oil immersion objective. Quantification of the data was
done using LSC software: 12-bit images were acquired by using
the same setting parameters for all the samples (gain, offset); for
each field, five different xy sections along the z axis were acquired.
Measurements were obtained for the nuclear fluorescence (Sn), the
total cell fluorescence (Sc), the area of the nucleus (An), and area of
the cell (Ac). The cytoplasmic (C9) amount of signal was calculated
as: C9=1 - [(An Sn)/(Ac Sc)]. C/N ratios were calculated as C/
N=C9/(1–C9).
Figure 6. Genotoxic stress modifies alternative splicing of endogenous genes. A. SH-SY5Y cells were incubated with vehicle or with PQ as
described in Material and Methods. The bar graph represents the quantification of the RT-PCR splicing analysis of the alternatively spliced regions of
the APAF1 (exon 18, e18), H-RAS (exon 5, e 5), ERCC1 (exon 8, e 8), SKP2 (exon 11, e 11), and BIN1 (exon 14, e14) transcripts. The indicated splice forms
were subcloned and sequenced to verify their identity. The inclusion or the skipping of variable exons after PQ treatment (black bars) was normalized
relative to that observed in the respective controls (light grey bars). Error bars indicate the standard error three biological replicates. The asterisks
represents the result of two-tailed t-test: *** indicates p,0.001, ** indicates p,0.01. B. RT-PCR splicing analysis of the alternatively spliced exon 18
(e18) of the APAF1 transcript in SH-SY5Y cells treated with vehicle (control), PQ, or c-radiation. The asterisks represents the result of one-way ANOVA
and Tukey’s post test: * indicates p,0.05. C. RT-PCR splicing analysis of the alternatively spliced exon 5 (e5) of the H-RAS transcript in SH-SY5Y cells
treated with vehicle, PQ, or cisplatin as described in Material and Methods. The asterisks represents the result of one-way ANOVA and Dunnett’s post
test: *** indicates p,0.001, ** indicates p,0.01.
doi:10.1371/journal.pone.0061980.g006
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Western blot analysis
Cells were lysed in lysis buffer (Tris HCl 50 mM pH 6.80, NaCl
150 mM, 1% NP40, 5 mM EGTA, 5 mM EDTA) with protease
inhibitors (Complete PIC, 04 693 116 001, Roche) and
phosphatase inhibitors (PhIC-1, P2850, Sigma; PhIC-2 P5726,
Sigma). Phosphatase treatment of total protein lysates was
performed with calf intestinal alkaline phosphatase was used
(CIP, New England Biolabs) following manufacturer’s instructions.
Proteins were separated in SDS-polyacrylamide gels and
transferred to nitrocellulose membranes (Whatman GmbH).
Membranes were blocked using 5% non fat dried milk in PBST
(0.1% (v/v) Tween 20 in 16 PBS) for 1 h at room temperature
and incubated with a primary antibody. The following primary
antibodies were used: mouse monoclonal anti-CPSF73K [38],
mouse monoclonal antibody mab 104 [16] mouse monoclonal
anti-SR proteins (clone 16H3, Invitrogen), mouse monoclonal
anti-SRp20 (clone 7B4, Invitrogen), mouse monoclonal anti-ASF/
SF2 (clone 96, Invitrogen), mouse monoclonal anti-ß actin
(ab8226, Abcam), mouse monoclonal anti-SRPK2 (BD Bioscienc-
es), mouse monoclonal anti-hnRNP K/J (clone 3C3, Sigma),
mouse monoclonal anti-hnRNP A1 (clone 4B10, Abcam), rabbit
polyclonal anti-hnRNP H (Novus Biological), mouse monoclonal
anti-hRNP C1/C2 (clone 4F4, Sigma), goat polyclonal anti-LDH
(Chemicon International), mouse monoclonal anti-FLAG-M2
(Sigma) mouse monoclonal anti-HA (Clone 6E2, Cell Signaling
Technology). After washing membranes were incubated with
peroxidase-conjugated secondary antibody anti-mouse IgG (GE
Healthcare), anti-goat IgG (Pierce), anti-rabbit IgG (Pierce,), anti-
mouse IgM (Santa Cruz Biotechnologies) and then detected with
ECL reagents (GE Healthcare).
RNA extraction and RT-PCR analysis of alternative
splicing
All the splicing analyses were performed on three independent
RNA preparations. Total RNA was from cultured cells extracted
using TRIzolH Reagent (Invitrogen), and subsequently purified
using silica membrane spin columns from RNeasy Mini kit
(Qiagen). RNA quantity and purity were assessed using a
NanoDropH instrument (Thermo Fisher Scientific Inc.). 2 mg of
total RNA were reverse-transcribed using MultiScriveTM Reverse
Transcriptase (Applied Biosystems), random hexamers (Applied
Biosystems), RNAsin Plus reagent (Promega) and dNTPs for 2 h at
37uC according to manufacture’s instruction. PCR assay condi-
tions were optimized for each gene with respect to primer
annealing temperatures, primer concentration, and MgCl2
concentrations. The number of amplification cycles used for each
reaction was determined to ensure that transcript amplification
was within a linear range (25 to 35 cycles). Gene specific primer
sequences are listed in Supporting Information, Table S1.
Quantification of the PCR products was performed with a 2100
Bioanalyzer (Agilent Technologies). Statistical analysis was per-
formed using GraphPad Instat software (GraphPad Software Inc.).
The amplified PCR products were cloned in pGEM T Easy
Vector System (Promega, Madison, USA) and sequenced by BMR
Genomics.
E1A splicing reporter assays
SH-SY5Y cells were either transfected with 5 mg of the reporter
construct alone or cotransfected with 5 mg of pME-HA-SRPK2
constructs as described above. Bluescript vector was used to
equalize the amount of total DNA transfected into the cell. Total
RNA was extracted using Trizol (Invitrogen) and passed into
RNeasy Mini Kit columns (Qiagen). After DNase treatment
(Promega), cDNA was synthesized from 1 mg of total RNA in a
20 ml reaction with oligo-dT primer (Promega) and M-MLV
Reverse Transcriptase (Promega). One ml was then used for PCR
amplification with GoTaq Flexi DNA Polymerase (Promega) using
the following E1A primers (59-TGAGTGCCAGCGAGTA-
GAGTTTTCT-39) and (59-TCTGGCTCGGGCTCAGGCT-
CAGGTT-39). Quantification of the PCR products was per-
formed with a 2100 Bioanalyzer (Agilent Technologies). Statistical
analysis was performed using GraphPad Instat software (Graph-
Pad Software Inc.).
Figure 7. Model of SRPK2 action inthe modulation of stress-dependent splicing. A. Under normal conditions SRPK2 is mainly located in the
cytoplasm. Its low level in the nucleus is counteracted by phosphatases that keep SR proteins in a hypophosphorylated state. B. Upon activation of
stress-dependent signalling (f. ex. induced by DNA damage) SRPK2 is phosphorlyated in serine 581 and translocates to the nucleus. Here, the
increased SRPK2 concentration overrides dephosphorlyation by PPases and leads to hyperphosphorylation of SR proteins. Since hyperpho-
sphorylation of the RS domain is detrimental for splicing activity, this results in the reduction of the active pool of SR proteins and to a change in the
balance between SR proteins and hnRNP proteins thus modifying the choice of alternative splice sites.
doi:10.1371/journal.pone.0061980.g007
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Statistical analysis
Continuous variables are expressed as means 6 SEM. The
averages and SEMs were calculated from at least three indepen-
dent experiments. Means of two-groups experiments were
compared with t-test (unpaired or paired, according to the fact
that data were respectively coupled or not). Means of multiple-
groups experiments were compared using one-way ANOVA,
Tukey post-test analysis, or Dunnett’s post hoc test. All the
analyses were performed using GraphPad prism 5.0 and
GraphPad Instat 3. A P value of *P,0.05 was considered
statistically significant, **P,0.01 was considered very significant,
***P,0.001 was considered extremely significant.
Supporting Information
Figure S1 Quantitative analysis of nuclear speckles in
PQ-treated cells. A. SH-SY5Y cells treated with vehicle or with
PQ were immunostained with an antiSC35 monoclonal antibody.
B. Anti-SC35 immunostained nuclear speckles in control SH-
SY5Y cells (white bars) and in cells treated with PQ (black bars).
While PQ affects neither the number nor the intensity of SC35-
positive nuclear speckles, their size becomes significantly larger
upon treatment. Quantification of the confocal micrographs was
performed with the LSC Data Analysis Software on n= 5
representative cells. Samples measurements were obtained for
the total area for each single speckle in each cell (pixel number in
the considered region of interest ROI), mean amplitude of the
pixel intensity for each single speckle in each cell (pixel intensity in
the ROI), total number of speckles per each cell. Values shown are
the mean 6 SEM obtained from 17.663.3 nuclear speckles in five
control cells and 14.0 6 3.5 nuclear speckles in five PQ-treated
cells respectively.
(TIFF)
Figure S2 PQ treatment does not modify the expression
level of hnRNP proteins. Total extract of control or PQ-
treated cells was probed with monoclonal antibodies to specific for
hnRNP A1, hnRNP C1/C2, hnRNP K/J, or hnRNP H.
(TIFF)
Figure S3 Intracellular distribution of SRPK2 mutant
proteins. A. Schematic diagram of the domain structure of wild
type SRPK2 and of its mutant variants. B. Representative confocal
micrographs of SH-SY5Y cell transfected with constructs
expressing the indicated HA-tagged SRPK2 proteins.
(TIF)
Table S1 Nucleotide sequences of the primers used for
alternative splicing analysis.
(DOC)
Table S2 Oligonucleotides used to generate the SRPK2
mutants.
(DOC)
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